AriBio said Thursday it has signed an exclusive global licensing agreement with Fosun Pharma worth up to $4.7 billion for AR1001, its oral Alzheimer’s disease treatment candidate.
Executives from Fosun Pharma and AriBio pose during a signing ceremony for AR1001’s global licensing agreement at Fosun Pharma’s headquarters in Shanghai, China, Wednesday. Second from left are Fosun Group Chairman Guo Guangchang, Fosun Pharma Chairman Chen Yuqing, AriBio Chairman and co-CEO Jai Jun Choung, AriBio co-CEO Soo-Hyun Sung and AriBio special adviser Rhee Byung-gun. (Credit: AriBio)
Under the agreement, Fosun Pharma will secure exclusive rights to develop, seek regulatory approval for, manufacture and commercialize AR1001 in global markets excluding Korea, the Middle East and Latin America. The two companies signed the agreement in Shanghai on Wednesday.
The deal expands the companies’ existing partnership, which had covered China and ASEAN markets, to major global markets including the U.S., Europe and Japan. AriBio said Fosun Pharma has also begun discussions for a large-scale direct investment in the Korean biotech company following the licensing agreement.
According to the company, the total potential value of the contract is about 7 trillion won ($4.7 billion) including upfront payments, option fees, milestone payments and royalties. AriBio will first receive $60 million, or about 90 billion won, as an option fee to support clinical development.
The company will receive an additional $80 million when topline results from its phase 3 trial are released, bringing the staged upfront payments to $140 million. AriBio will also be eligible for milestone payments tied to regulatory approval and commercialization, as well as royalties of up to around 20 percent.
AR1001 is AriBio’s independently developed oral phosphodiesterase-5 inhibitor for Alzheimer’s disease. The drug candidate is being developed as a disease-modifying therapy intended to address underlying mechanisms of the disease rather than only symptoms.
The candidate is being evaluated in the global phase 3 POLARIS-AD trial, which has enrolled more than 1,500 patients in major markets including the U.S., Europe, the U.K., China and Korea. The study is in its final stage, with topline results expected in 2026.
Alzheimer’s disease drug development has historically carried a high failure rate in late-stage clinical trials, although recent approvals of anti-amyloid therapies have renewed investment in the field.
AriBio said AR1001 is designed to target multiple mechanisms associated with Alzheimer’s disease, including amyloid and tau pathology, neuroinflammation and cerebral blood flow.
AriBio said clinical data generated so far have shown favorable safety, blood-brain barrier penetration and the potential to improve cognitive function in early-stage patients. The company said the latest deal reflects Fosun Pharma’s confidence in the commercial potential of AR1001 before the completion of the phase 3 trial and before topline data are released.
“This global licensing agreement is an example of a Korean biotech company securing a major partnership in the global new drug market,” AriBio co-CEO Choung Jai-jun said. “It is a meaningful milestone reflecting recognition of AriBio’s technology and long-term investment in Alzheimer’s disease drug development.”
Choung added that the two companies plan to work closely to accelerate development and expand treatment access globally.
Fosun Group Chairman Guo Guangchang also pointed to the unmet need in Alzheimer’s disease, an area known for high clinical development risk.
“In the field of Alzheimer’s disease drug development, which is known for its low probability of success, we judged AR1001 to be a promising asset in terms of innovation and global potential,” Guangchang said.
Fosun Pharma Chairman Chen Yuqing said positive phase 3 results could strengthen AR1001’s competitiveness in the global Alzheimer’s treatment market.
Lee Han-soo
댓글
0